Bennu Biotherapeutics

Bennu Biotherapeutics is an early-stage biotechnology company focused on developing next-generation T-cell therapies for cancer and chronic infectious diseases. Founded by pioneers in immunology and cell therapy from the University of Pennsylvania, the company leverages proprietary insights into the molecular mechanisms of T-cell exhaustion and epigenetic reprogramming. Their core technology aims to "reinvigorate" exhausted T cells by targeting master regulators like the TOX protein, potentially overcoming a major limitation of current CAR-T and TCR therapies in solid tumors. By restoring the durability and potency of immune cells within the suppressive tumor microenvironment, Bennu seeks to create more effective and long-lasting treatments for patients with hard-to-treat malignancies. The company operates at the intersection of advanced cell engineering and deep immunological research.